NetworkNewsBreaks – Lexaria Bioscience Corp.’s
Post# of 420
(Total Views: 151)
Posted On: 05/18/2023 4:43:30 PM
NetworkNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Study Demonstrates Significant Enhancement in Oral Estradiol Delivery
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced successful completion of its animal study HOR-A22-1, showing significant enhancement in the oral delivery of the estrogen hormone estradiol, an important component of therapeutic products in the women’s health sector. According to the update, the DehydraTECH-estradiol formulation achieved an average peak concentration in the bloodstream (or “Cmax”) of 5.65ng/mL, roughly nine times (900%) higher than that achieved with the control formulation at only 0.63 ng/mL. In addition, with estradiol known to be quickly converted into the metabolite estrone by cells in the uterus, mammary glands and liver, estrone levels were also quantified in the study. The results revealed levels of the estrone metabolite significantly higher comparing an average Cmax of 6.49 ng/mL with the DehydraTECH formulation to only 0.302 ng/mL achieved with the control. This represents greater than a twenty-fold (2,000%) improvement in delivery.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced successful completion of its animal study HOR-A22-1, showing significant enhancement in the oral delivery of the estrogen hormone estradiol, an important component of therapeutic products in the women’s health sector. According to the update, the DehydraTECH-estradiol formulation achieved an average peak concentration in the bloodstream (or “Cmax”) of 5.65ng/mL, roughly nine times (900%) higher than that achieved with the control formulation at only 0.63 ng/mL. In addition, with estradiol known to be quickly converted into the metabolite estrone by cells in the uterus, mammary glands and liver, estrone levels were also quantified in the study. The results revealed levels of the estrone metabolite significantly higher comparing an average Cmax of 6.49 ng/mL with the DehydraTECH formulation to only 0.302 ng/mL achieved with the control. This represents greater than a twenty-fold (2,000%) improvement in delivery.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LEXX) Stock Research Links
Scroll down for more posts ▼